S&P 500   4,127.65 (-0.30%)
DOW   32,812.14 (-0.06%)
QQQ   316.59 (-1.28%)
AAPL   164.23 (-0.39%)
MSFT   279.90 (-0.15%)
META   167.72 (-1.49%)
GOOGL   116.11 (-1.01%)
AMZN   137.13 (-1.64%)
TSLA   858.95 (-1.41%)
NVDA   171.19 (-3.79%)
NIO   19.46 (-3.52%)
BABA   91.60 (+0.84%)
AMD   96.30 (-3.77%)
MU   58.63 (-4.59%)
T   18.15 (+0.83%)
CGC   3.01 (-8.23%)
GE   75.81 (+0.84%)
F   15.50 (-1.77%)
DIS   107.40 (-1.57%)
AMC   22.87 (-4.55%)
PYPL   94.17 (-2.17%)
PFE   49.68 (+0.22%)
NFLX   226.88 (-2.83%)
S&P 500   4,127.65 (-0.30%)
DOW   32,812.14 (-0.06%)
QQQ   316.59 (-1.28%)
AAPL   164.23 (-0.39%)
MSFT   279.90 (-0.15%)
META   167.72 (-1.49%)
GOOGL   116.11 (-1.01%)
AMZN   137.13 (-1.64%)
TSLA   858.95 (-1.41%)
NVDA   171.19 (-3.79%)
NIO   19.46 (-3.52%)
BABA   91.60 (+0.84%)
AMD   96.30 (-3.77%)
MU   58.63 (-4.59%)
T   18.15 (+0.83%)
CGC   3.01 (-8.23%)
GE   75.81 (+0.84%)
F   15.50 (-1.77%)
DIS   107.40 (-1.57%)
AMC   22.87 (-4.55%)
PYPL   94.17 (-2.17%)
PFE   49.68 (+0.22%)
NFLX   226.88 (-2.83%)
S&P 500   4,127.65 (-0.30%)
DOW   32,812.14 (-0.06%)
QQQ   316.59 (-1.28%)
AAPL   164.23 (-0.39%)
MSFT   279.90 (-0.15%)
META   167.72 (-1.49%)
GOOGL   116.11 (-1.01%)
AMZN   137.13 (-1.64%)
TSLA   858.95 (-1.41%)
NVDA   171.19 (-3.79%)
NIO   19.46 (-3.52%)
BABA   91.60 (+0.84%)
AMD   96.30 (-3.77%)
MU   58.63 (-4.59%)
T   18.15 (+0.83%)
CGC   3.01 (-8.23%)
GE   75.81 (+0.84%)
F   15.50 (-1.77%)
DIS   107.40 (-1.57%)
AMC   22.87 (-4.55%)
PYPL   94.17 (-2.17%)
PFE   49.68 (+0.22%)
NFLX   226.88 (-2.83%)
S&P 500   4,127.65 (-0.30%)
DOW   32,812.14 (-0.06%)
QQQ   316.59 (-1.28%)
AAPL   164.23 (-0.39%)
MSFT   279.90 (-0.15%)
META   167.72 (-1.49%)
GOOGL   116.11 (-1.01%)
AMZN   137.13 (-1.64%)
TSLA   858.95 (-1.41%)
NVDA   171.19 (-3.79%)
NIO   19.46 (-3.52%)
BABA   91.60 (+0.84%)
AMD   96.30 (-3.77%)
MU   58.63 (-4.59%)
T   18.15 (+0.83%)
CGC   3.01 (-8.23%)
GE   75.81 (+0.84%)
F   15.50 (-1.77%)
DIS   107.40 (-1.57%)
AMC   22.87 (-4.55%)
PYPL   94.17 (-2.17%)
PFE   49.68 (+0.22%)
NFLX   226.88 (-2.83%)
NYSE:CRL

Charles River Laboratories International - CRL Stock Forecast, Price & News

$215.79
-4.89 (-2.22%)
(As of 08/9/2022 10:28 AM ET)
Add
Compare
Today's Range
$215.43
$221.51
50-Day Range
$204.13
$250.54
52-Week Range
$203.37
$460.21
Volume
2,676 shs
Average Volume
531,558 shs
Market Capitalization
$10.98 billion
P/E Ratio
25.03
Dividend Yield
N/A
Price Target
$355.64

Charles River Laboratories International MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.77 Rating Score
Upside/​Downside
64.0% Upside
$353.82 Price Target
Short Interest
Healthy
2.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
-0.17mentions of Charles River Laboratories International in the last 14 days
Based on 35 Articles This Week
Insider Trading
Selling Shares
$86,337 Sold Last Quarter
Proj. Earnings Growth
14.94%
From $10.78 to $12.39 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.80 out of 5 stars

Medical Sector

59th out of 1,098 stocks

Commercial Physical Research Industry

3rd out of 17 stocks

CRL stock logo

About Charles River Laboratories International (NYSE:CRL) Stock

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Charles River Laboratories International Trading Down 1.2 %

CRL Stock opened at $220.68 on Tuesday. The company has a market capitalization of $11.21 billion, a PE ratio of 25.60, a price-to-earnings-growth ratio of 1.48 and a beta of 1.29. Charles River Laboratories International has a one year low of $203.37 and a one year high of $460.21. The company's 50 day moving average price is $225.61 and its two-hundred day moving average price is $260.19. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.08 and a current ratio of 1.33.

Charles River Laboratories International (NYSE:CRL - Get Rating) last released its quarterly earnings results on Wednesday, August 3rd. The medical research company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.74 by $0.03. The business had revenue of $973.13 million for the quarter, compared to analysts' expectations of $995.12 million. Charles River Laboratories International had a net margin of 12.02% and a return on equity of 21.51%. The firm's revenue for the quarter was up 6.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.61 earnings per share. As a group, analysts predict that Charles River Laboratories International will post 10.78 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on CRL. Stephens set a $315.00 price target on shares of Charles River Laboratories International in a research report on Monday, June 20th. Jefferies Financial Group lowered shares of Charles River Laboratories International from a "buy" rating to a "hold" rating and cut their target price for the stock from $370.00 to $280.00 in a research report on Monday, April 25th. Wells Fargo & Company cut their price objective on shares of Charles River Laboratories International from $390.00 to $325.00 and set an "overweight" rating for the company in a research report on Monday, April 25th. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Charles River Laboratories International from $290.00 to $270.00 in a research report on Monday. Finally, Morgan Stanley lowered shares of Charles River Laboratories International from an "overweight" rating to an "equal weight" rating and cut their price objective for the company from $350.00 to $250.00 in a research report on Thursday, August 4th. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International has a consensus rating of "Moderate Buy" and an average price target of $353.82.

Insider Activity

In other news, EVP Joseph W. Laplume sold 200 shares of the business's stock in a transaction on Friday, August 5th. The shares were sold at an average price of $226.13, for a total transaction of $45,226.00. Following the sale, the executive vice president now owns 20,766 shares in the company, valued at approximately $4,695,815.58. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 1.10% of the company's stock.

Receive CRL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter.

CRL Stock News Headlines

These 2 Stocks May Be Recession-Proof
Analyst Ratings for Charles River
See More Headlines
Receive CRL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter.

CRL Company Calendar

Last Earnings
8/03/2022
Today
8/09/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
CUSIP
15986410
Employees
20,000
Year Founded
1947

Price Target and Rating

Average Stock Price Forecast
$353.82
High Stock Price Forecast
$480.00
Low Stock Price Forecast
$250.00
Forecasted Upside/Downside
+64.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.77
Research Coverage
13 Analysts

Profitability

Net Income
$390.98 million
Pretax Margin
14.69%

Debt

Sales & Book Value

Annual Sales
$35.40 billion
Cash Flow
$15.23 per share
Book Value
$50.29 per share

Miscellaneous

Free Float
50,304,000
Market Cap
$10.98 billion
Optionable
Optionable
Beta
1.29

Social Links















CRL Stock - Frequently Asked Questions

Should I buy or sell Charles River Laboratories International stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories International in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRL shares.
View CRL analyst ratings
or view top-rated stocks.

What is Charles River Laboratories International's stock price forecast for 2022?

13 equities research analysts have issued 1 year target prices for Charles River Laboratories International's stock. Their CRL share price forecasts range from $250.00 to $480.00. On average, they expect the company's share price to reach $353.82 in the next twelve months. This suggests a possible upside of 60.3% from the stock's current price.
View analysts price targets for CRL
or view top-rated stocks among Wall Street analysts.

How has Charles River Laboratories International's stock price performed in 2022?

Charles River Laboratories International's stock was trading at $376.78 at the start of the year. Since then, CRL stock has decreased by 41.4% and is now trading at $220.68.
View the best growth stocks for 2022 here
.

When is Charles River Laboratories International's next earnings date?

Charles River Laboratories International is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our CRL earnings forecast
.

How were Charles River Laboratories International's earnings last quarter?

Charles River Laboratories International, Inc. (NYSE:CRL) announced its earnings results on Wednesday, August, 3rd. The medical research company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.74 by $0.03. The medical research company earned $973.13 million during the quarter, compared to analysts' expectations of $995.12 million. Charles River Laboratories International had a trailing twelve-month return on equity of 21.51% and a net margin of 12.02%. The company's quarterly revenue was up 6.4% on a year-over-year basis. During the same period in the previous year, the business earned $2.61 EPS.
Read the conference call transcript
.

What guidance has Charles River Laboratories International issued on next quarter's earnings?

Charles River Laboratories International issued an update on its FY 2022 earnings guidance on Wednesday, August, 3rd. The company provided earnings per share (EPS) guidance of $10.70-$10.95 for the period, compared to the consensus earnings per share estimate of $11.53. The company issued revenue guidance of $3.86 billion-$3.93 billion, compared to the consensus revenue estimate of $4.01 billion.

What is James C. Foster's approval rating as Charles River Laboratories International's CEO?

291 employees have rated Charles River Laboratories International Chief Executive Officer James C. Foster on Glassdoor.com. James C. Foster has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Charles River Laboratories International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Charles River Laboratories International investors own include NVIDIA (NVDA), Boeing (BA), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA), Salesforce (CRM), Abbott Laboratories (ABT), Mastercard (MA), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

What is Charles River Laboratories International's stock symbol?

Charles River Laboratories International trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

Who are Charles River Laboratories International's major shareholders?

Charles River Laboratories International's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (1.27%), Congress Asset Management Co. MA (0.91%), Montrusco Bolton Investments Inc. (0.60%), Horizon Kinetics Asset Management LLC (0.59%), Riverbridge Partners LLC (0.54%) and TimesSquare Capital Management LLC (0.47%). Insiders that own company stock include Birgit Girshick, David Ross Smith, Deborah Turner Kochevar, George Massaro, James C Foster, James C Foster, Joseph W Laplume, Michael Gunnar Knell, Richard F Wallman, Robert J Bertolini, Stephen D Chubb, Victoria L Creamer, William D Barbo and William D Barbo.
View institutional ownership trends
.

How do I buy shares of Charles River Laboratories International?

Shares of CRL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Charles River Laboratories International's stock price today?

One share of CRL stock can currently be purchased for approximately $220.68.

How much money does Charles River Laboratories International make?

Charles River Laboratories International (NYSE:CRL) has a market capitalization of $11.21 billion and generates $35.40 billion in revenue each year. The medical research company earns $390.98 million in net income (profit) each year or $8.62 on an earnings per share basis.

How many employees does Charles River Laboratories International have?

Charles River Laboratories International employs 20,000 workers across the globe.

Does Charles River Laboratories International have any subsidiaries?

The following companies are subsidiares of Charles River Laboratories International: 3313290 Nova Scotia Company, 9904140 Canada Inc., Accugenix Inc., Agilux Laboratories, Argenta Discovery 2009 Limited, Ballardvale C.V., Beijing Vital River Laboratory Animal Technology Co. Ltd., BioFocus DPI (Holdings) Ltd., Biological Laboratories Europe Ltd. ("BioLabs"), Blue Stream Laboratories, Brains On-Line, CRL Dutch Holding Company B.V., CRL Group France, CRL Group International France, CRL Holding Germany GmbH, CRL Holding Netherlands B.V., CRL Safety Assessment Inc., Celsis Group Limited, Celsis International, Celsis International B.V., Celsis International GmbH, Celsis International Limited, Celsis Limited, Cerebricon, Chantest, Charles River Detecção Microbiana e de Endotoxina Participações Ltda, Charles River Discovery Research Services Finland, Charles River Discovery Research Services Germany GmbH, Charles River Discovery Research Services Inc., Charles River Discovery Research Services International Inc., Charles River Discovery Research Services UK Limited, Charles River Endotoxin Microbial Detection Europe SAS, Charles River Endotoxin and Microbial Detection Israel, Charles River Endotoxin and Microbial Detection Singapore Pte. Ltd., Charles River Germany GmbH & Co. KG, Charles River Germany Verwaltungs GmbH, Charles River Holdings LLC, Charles River Laboratories Ashland LLC, Charles River Laboratories Asia Holdings Limited, Charles River Laboratories Australia Pty. Ltd., Charles River Laboratories Belgium SPRL, Charles River Laboratories Cleveland Inc., Charles River Laboratories Copenhagen, Charles River Laboratories Den Bosch B.V., Charles River Laboratories Edinburgh Ltd., Charles River Laboratories España SA, Charles River Laboratories Evreux, Charles River Laboratories France Safety Assessment SAS, Charles River Laboratories France-C.R.L.F. SAS, Charles River Laboratories Germany GmbH, Charles River Laboratories Group, Charles River Laboratories Holding Europe SAS, Charles River Laboratories Holding SAS, Charles River Laboratories Holdings Limited, Charles River Laboratories Hungary, Charles River Laboratories I Delaware Holdings Inc., Charles River Laboratories II Delaware Holdings Inc., Charles River Laboratories Inc., Charles River Laboratories India Private Limited, Charles River Laboratories Ireland Holding Unlimited Company, Charles River Laboratories Ireland Limited, Charles River Laboratories Italia Srl, Charles River Laboratories Japan Inc., Charles River Laboratories Korea, Charles River Laboratories Luxembourg S.a.r.l., Charles River Laboratories Montreal ULC, Charles River Laboratories Poland Sp. Z.o.o., Charles River Laboratories Research Models and Services Germany GmbH, Charles River Laboratories SA France Acquisition SAS, Charles River Laboratories SA France Holdings SAS, Charles River Laboratories SA Japan KK, Charles River Laboratories SA Netherlands Holdings B.V., Charles River Laboratories SA USA Inc., Charles River Laboratories Saint Nazaire, Charles River Laboratories Saint‑Constant S.A., Charles River Microbial Solutions Company (Shanghai) Limited, Charles River Microbial Solutions International Limited, Charles River Nederland B.V., Charles River UK Limited, Charles River ULC, CiToxLAB, Citox Inc., Citoxlab USA LLC, Cognate BioServices, Genetic Models, HemaCare, Inveresk Research, KWS BioTest, KWS BioTest Limited, MPI Research, Molecular Therapeutics, Nastor Investments, NewLab BioQuality AG, Northwest Kinetics, Oncotest, Pathology Associates International Corporation, Piedmont Research Center, Primedica, Retrogenix Limited, River Valley Farms, Saothorlanna Bitheolaiocha Idirnaisiunta Teoranta, Sierra Biomedical, Solvo Biotechnology USA Inc., Solvo Biotechnológiai Zrt, Springborn Laboratories, Sunrise Farms Inc., Systems Pathology Company LLC, Tektagen Inc, Vigene Biosciences Inc., WIL Research, Zhanjiang A&C Biological Ltd., and Zhejiang Vital River Laboratory Animal Technology Co. Ltd..
Read More

When was Charles River Laboratories International founded?

Charles River Laboratories International was founded in 1947.

How can I contact Charles River Laboratories International?

Charles River Laboratories International's mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The official website for the company is www.criver.com. The medical research company can be reached via phone at (781) 222-6000, via email at askcharlesriver@crl.com, or via fax at 978-988-5665.

This page (NYSE:CRL) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.